PHARMA LITERATI

Events Date Place Sponsor World Hepatitis Day 28 th July Not applicable World Health Organization Indian Pharmacovigilance day 2016 conference 29 th July Mumbai Oviya MedSafe ICIPS-2016_1st International conference on innovations in pharmaceutical sciences 29 th & 30 th July Hyderabad Guru Nanak Institutions technical Campus School of Pharmacy National Level Conference On Recent Trends In Pharma Sciences And Life Sciences 28 th August NSIC, Hyderabad Anveshnana Educational and Research Foundation FICCI   Healthcare Excellence Awards 31 st August Delhi FICCI 1st Conference of the Indian Society for the Study of Xenobiotics (SSX®) 1 st to 3 rd September IISC Bangalore Indian Society for Study of Xenobiotics (SSX®)

World hepatitis day 2016 would be celebrated by the people all over the world on 28 th  of July, at Thursday. The theme for this year’s global campaign is ELIMINATION . History: In 2010 the World Health Organization made World Hepatitis Day one of only four official disease-specific world health days, to be celebrated each year on the 28th July. Millions of people across the world now take part in World Hepatitis Day, to raise awareness about viral hepatitis, and to call for access to treatment, better prevention programs and government action. 2016 is a pivotal year for viral hepatitis. At the World Health Assembly in May, WHO Member States are set to adopt the first ever Elimination Strategy for Viral Hepatitis, with ambitious targets and a goal to eliminate hepatitis as a public health threat by 2030 . This will be the first time national governments sign up and commit to the goal of eliminating viral hepatitis. Details: http://worldhepatitisday.org/en/about-us

Friday, 29 July 2016 - Mumbai, Peninsula Grand Hotel.  Pharmacovigilance is a domain that involves a variety of stakeholders such as pharmaceutical manufacturers, drug marketers, contract research organizations, regulators, healthcare professionals, subject matter experts and the consumers, among others. India is globally recognized as an important hub for generic drug manufacturing and the Indian pharmaceutical industry has carved a niche for itself in exporting its products to many developed as well as emerging countries. Of late, India is also being seen as a target destination for procurement of support services required for the global pharmaceutical industry, with pharmacovigilance outsourcing having grown to an impressive extent in the past decade. Simultaneously, newer developments in Indian Pharmacovigilance have occurred which include a requirement for XML-E2B format reporting of ICSRs by the pharmaceutical industry to the Pharmacovigilance Programme of India

Trouble is brewing at Abbott, India's second-largest drug maker by market share, following an alleged suicide last week by a medical representative in Indore purportedly under pressure to achieve periodic sales targets. Abbott has strongly refuted any role in the employee's death, noting that the deceased was rated among the top performers and had recently qualified for a training certification meant for high performers. Ashish Awasthi, who was 35, was found dead on a railway track last week. A note recovered from him blamed the company for his death. The incident sparked unrest among Abbott's local field representatives, who have staged a series of demonstrations, demanding adequate compensation for the dead employee's family and better service conditions for field representatives. Members of the union of medical representatives have written to the company's top executives in India and its headquarters in Chicago, highlighting, what they termed, continuous

India's Supreme Court had directed drug maker Cipla to deposit a sum of Rs 175.07 crore within six weeks in a case related to alleged overcharging in certain drugs as per the provisions of Drug (Price Control) Order, 1995.   In a note to stock exchanges late on Friday, Cipla said the writ petitions filed in the Bombay High Court that were pending before Supreme Court have been retransferred to the Bombay High Court for final hearing. The initial order for the deposits was issued by Supreme Court in 2003, which had directed the government to recover 50% of the overcharged amount by the company.   "The Bombay High Court will now hear these matters on merits," the drug maker said. Cipla and India's drug pricing watchdog have been in a drawn-out legal tussle. The authority has charged Cipla of charging higher prices for a set of drugs than the ceiling price based on a fixed formula. Source: http://economictimes.indiatimes.com/industry/healthcare/biotech/pha

Economic times recently carried out an interesting article on India's next generation of women leaders. This article covers various women leaders who have made their mark in different fields of life sciences. 1. Namita Thapar 39 CFO, Emcure Pharmaceuticals 2. Zahabiya Khorakiwala 33 Managing Director, Wockhardt Hospitals 3. Tara Singh Vachani 29 CEO & Managing Director - Antara Senior Living 4. Ameera Shah 36, Managing Director, Metropolis Labs 5. Samina Vaziralli 37 Executive Director, Cipla Link:  http://economictimes.indiatimes.com/small-biz/entrepreneurship/meet-indias-next-generation-of-women-leaders-in-pharma/articleshow/53273951.cms

Maharashtra Food and Drug Administration (FDA) has detected cases of leading brands in the country promoting skin creams as OTC drugs for treatment of skin ailments through self-medication in violation of labelling conditions of the Drugs and Cosmetic Rules, 1945 .  The state regulator is planning to take action against the companies as provisioned under Rule 106 to be read along with Schedule J and Section 18 (6). Stocks worth over Rs.70, 000 have already been seized from retailers in Mumbai alone. State regulator had earlier seized such steroid-laden creams from different locations in the state and detected two such cases in the past of products UB Fair for men and No Scars cream for women contain steroids like fluocinolon acetonid and mometasone along with skin bleaching agents. According to a senior FDA official, these skin creams violate the labeling conditions of the Drug Rules and make false claims of making a person fair despite the fact that they are mild ster

  FICCI presents the eighth edition of its annual Healthcare Excellence Awards supported by Quality Council of India on August 31, 2016 from 7:30 pm to 10:00 pm at The Le Meridian, New Delhi. Indian Healthcare Industry is experiencing new wave of opportunities due to robust domestic demand, rise in innovative healthcare, corporatization of healthcare facilities, influx of medical tourism and governments push towards Make in India. FICCI Healthcare Excellence Awards 2016 aims at felicitating organizations and individuals for their efforts towards operational excellence, innovatively adopting and inventing technologies and processes for India, and improved healthcare delivery. The FICCI Awards have emerged as the definitive recognition for contribution to healthcare in the country over the years.   Details available at: http://www.ficci-heal.com/bro1.pdf

At this juncture, when we are moving towards ‘ Digital India’ and are encouraging the use of technology in all services, it is important that we do not take any step which could be detrimental to the growth of this channel and restricts the consumers to access to all modes of distribution. Further to work towards the vision of ‘Digital Health’, e-pharmacy is again an important aspect which needs to be well considered in terms of better outreach to consumers. To better understand this new channel of distribution and to analyze its challenges and the ways to address them, FICCI has developed a white paper - 'ePharmacy in India - Last mile access of medicines'. The white paper will be released at a seminar on 25th of July, 2016 at FICCI, New Delhi office in the presence of Government dignitaries, Industry players and other concerned stakeholders.  

Anveshnana Educational and Research Foundation organizing eminent Pharmaceutical conferences welcomes you to attend the National Level Pharmacy conference to be held during August 28th, 2016 in NSIC. Ecil focuses on the advancements in pharmacy and Quality risk management. The field of Pharmacy is growing rapidly and its development is making tremendous impacts in Global world of pharmaceuticals. Emphasizes on how the importance and significance can be gauged by the fact that it has made huge advancements over the course of time and is continuing to influence various sectors. Main theme of International Pharmacy conference is “Innovations in exertions of Pharmacy”.   Venue: NSIC ( The National Small Industries Corp Ltd. ) Near Radhika X Roads, ECIL, Hyderabad, 500 062.    Early Bird Registration 01 st August 2016 Approval Notification 26 th August 2016 Final Paper Submission 26 th August 2016 Last Date o

The guidelines for Opening of Jan Aushadhi Store for different category are revised: • For - Individuals Entrepreneurs/Unemployed Pharmacists/Doctors/Registered Medical Practitoners • For - NGO Hospitals/Charitable Institutions/Private Hospitals/Trust/Societies/Self help Group • For - State Government Nominated Agencies • For - Mobile Jan Aushadhi Medical Store Scheme   The guidelines are available at: http://janaushadhi.gov.in/guidelines.html

   

Almost one-third (31 per cent) of those who claimed to be allopathic doctors in 2001 were educated only up to the secondary school level and 57 per cent did not have any medical qualification, a recent WHO report found, ringing the alarm bells on India’s healthcare workforce. The situation was far worse in rural India, where just 18.8 per cent of allopathic doctors had a medical qualification, the study titled ‘ The Health Workforce in India ’, published in June 2016, revealed. Speaking to The Hindu , Dr. Reena Nayyar, Secretary of the Medical Council of India (MCI), said, “I don’t think this report has officially come to the MCI yet. But in general, any person practising allopathic medicine who does not have a registered medical qualification comes under quackery.”  Interestingly, female healthcare workers – 38 per cent of the total – were found to be more educated and medically qualified than their male counterparts. For instance, among allopathic doctors, 67 per c

IIHMR University, Jaipur is organizing Management development program on Safeguarding Quality of Medicines in Resource – Limited Settings on 19 th to 23 rd September 2016. Details available at: https://iihmr.edu.in/pages/download?file=app/webroot/files/training/brochure/50/sqm-brochure.pdf OBJECTIVES OF THE PROGRAM The Specific objectives of the program are:- • To provide technical guidance for establishing a robust quality assurance framework for ensuring good quality of medicines in spite of limited human and financial resources; • To comprehend key concepts and principles pertaining to quality of medicines; • To underline the key issues and challenges affecting the quality of medicines in the existing healthcare systems and identifying the ways to mitigate the quality issues PROGRAM CONTENTS • Significance of quality assurance & quality control activities in ensuring quality of medicines (Examples and case studies related to HIV, TB, Malaria, Antib

The admission time is here. If you are planning for an MBA course in near future, this one is for you.  Become a better negotiator, attend the Master class on ' Leadership, Influence and Decision Making '​ by Professor Dishan Kamdar on July 24 in Mumbai. Request an invitation for the session. *Participation is by invitation only. The form is available at http://isbadmissions.isb.edu/master-class-mumbai This session will be beneficial to everyone whose work involves negotiating with subordinates, peers, superiors and vendors. Those who seek to better understand the strengths and weaknesses of their own negotiation style and strategic habits, improve their own negotiation performance and enhance the quality of their negotiated settlements will benefit from this class. About the speaker: Prof Kamdar is a Senior Faculty and the Deputy Dean at the Indian School of Business.  He holds a PhD and an MSc in Management from the National University of Singapore.